Ou Sai-Hong Ignatius, Nagasaka Misako
Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California.
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
JTO Clin Res Rep. 2020 Apr 28;1(3):100048. doi: 10.1016/j.jtocrr.2020.100048. eCollection 2020 Sep.
fusion-positive () NSCLC was discovered in 2007, the same year as the discovery of -positive (+) NSCLC but has trailed + NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which depend on fusion partners (CD74, SLC34A2, or SDC4); thus, knowledge of the fusion partners in NSCLC is important. To date (end of February 2020), we have identified 24 unique 5' fusion partners of in NSCLC from published literature and congress proceedings. Thus, we published this catalog for easy reference.
融合阳性（）非小细胞肺癌于2007年被发现，同年发现了阳性（+）非小细胞肺癌，但在发展方面落后于+非小细胞肺癌。对于ROS1抑制剂似乎存在不同的反应，这取决于融合伴侣（CD74、SLC34A2或SDC4）；因此，了解非小细胞肺癌中的融合伴侣很重要。截至（2020年2月底），我们已从已发表的文献和会议记录中确定了非小细胞肺癌中24个独特的5'融合伴侣。因此，我们发布此目录以便于参考。
